TW200740458A - Vaccination against dengue virus infection - Google Patents

Vaccination against dengue virus infection

Info

Publication number
TW200740458A
TW200740458A TW095129386A TW95129386A TW200740458A TW 200740458 A TW200740458 A TW 200740458A TW 095129386 A TW095129386 A TW 095129386A TW 95129386 A TW95129386 A TW 95129386A TW 200740458 A TW200740458 A TW 200740458A
Authority
TW
Taiwan
Prior art keywords
virus infection
dengue virus
vaccination against
against dengue
vaccination
Prior art date
Application number
TW095129386A
Other languages
English (en)
Chinese (zh)
Inventor
Thomas P Monath
Farshad Guirakhoo
Niranjan Kanesa-Thasan
Thomas H Ermak
Jean Lang
Forrat Remi
Original Assignee
Acambis Inc
Sanofi Pasteur Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acambis Inc, Sanofi Pasteur Sa filed Critical Acambis Inc
Publication of TW200740458A publication Critical patent/TW200740458A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW095129386A 2005-08-10 2006-08-10 Vaccination against dengue virus infection TW200740458A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70703805P 2005-08-10 2005-08-10
US71944805P 2005-09-22 2005-09-22

Publications (1)

Publication Number Publication Date
TW200740458A true TW200740458A (en) 2007-11-01

Family

ID=37758084

Family Applications (1)

Application Number Title Priority Date Filing Date
TW095129386A TW200740458A (en) 2005-08-10 2006-08-10 Vaccination against dengue virus infection

Country Status (12)

Country Link
US (1) US20080193477A1 (enExample)
EP (1) EP1924280A4 (enExample)
JP (1) JP5227172B2 (enExample)
AR (1) AR055603A1 (enExample)
AU (1) AU2006280144B2 (enExample)
BR (1) BRPI0614265A2 (enExample)
CA (1) CA2618783A1 (enExample)
IL (1) IL189329A (enExample)
MY (1) MY151051A (enExample)
NO (1) NO20081127L (enExample)
TW (1) TW200740458A (enExample)
WO (1) WO2007021672A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113637694A (zh) * 2013-03-15 2021-11-12 武田疫苗股份有限公司 用于疫苗中的登革热病毒嵌合式构建物的组合物及方法

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2903605A1 (fr) * 2006-07-12 2008-01-18 Sanofi Pasteur Sa Methode d'immunisation contre les quatres serotypes de la dengue
FR2906724B1 (fr) * 2006-10-04 2009-03-20 Sanofi Pasteur Sa Methode d'immunisation contre les 4 serotypes de la dengue.
FR2909286B1 (fr) * 2006-12-01 2012-06-08 Sanofi Pasteur Methode d'immunisation contre les 4 serotypes de la dengue
US8968996B2 (en) 2009-06-01 2015-03-03 Takeda Vaccines, Inc. Compositions and methods for rapid immunization against dengue virus
NZ618158A (en) * 2009-06-01 2015-05-29 Takeda Vaccines Inc Compositions and methods for administration of vaccines against dengue virus
BRPI0904020B8 (pt) 2009-10-01 2021-05-25 Fundacao Oswaldo Cruz composição vacinal contra o vírus da dengue, e, kit
WO2013151764A1 (en) * 2012-04-02 2013-10-10 The University Of North Carolina At Chapel Hill Methods and compositions for dengue virus epitopes
WO2014016362A1 (en) 2012-07-24 2014-01-30 Sanofi Pasteur Vaccine compositions for prevention against dengue virus infection
EP3932422A1 (en) 2012-07-24 2022-01-05 Sanofi Pasteur Vaccine compositions for the prevention of dengue virus infection
BR112015012515B1 (pt) 2012-11-30 2023-04-11 Sanofi Pasteur Uso de antígenos, construções de ácido nucleico ou vetores virais capazes de expressar uma partícula do tipo vírus (vlp) da dengue e de uma vacina contra sarampo, uma vacina contra caxumba e uma vacina contra rubéola
CA2933472A1 (en) 2012-12-14 2014-06-19 Takeda Vaccines, Inc. Compositions, methods of administration and uses for trivalent dengue virus formulations
SG10201807826XA (en) 2014-02-11 2018-10-30 Massachusetts Inst Technology Novel full spectrum anti-dengue antibody
GB201704126D0 (en) * 2017-03-15 2017-04-26 Blom Nihlén Kim Andrea Vaccine
EP3601543A4 (en) * 2017-03-30 2021-01-27 Merck Sharp & Dohme Corp. ADDING NUCLEASES DIRECTLY TO CELL CULTURE TO FACILITATE DIGESTION AND RELEASE OF HOST CELL NUCLEIC ACIDS
SG11202002933TA (en) 2017-10-05 2020-04-29 Sanofi Pasteur Compositions for booster vaccination against dengu
CA3111332A1 (en) 2018-09-05 2020-03-12 Takeda Vaccines, Inc. Dengue vaccine unit dose and administration thereof
AU2020331884B2 (en) 2019-08-16 2025-01-23 Takeda Vaccines, Inc. Methods for preventing dengue and Hepatitis A
EP4110381A1 (en) 2020-02-27 2023-01-04 Takeda Vaccines, Inc. Method for removing host cell dna from virus preparation
WO2023147342A2 (en) 2022-01-25 2023-08-03 Takeda Vaccines, Inc. Large-scale flaviviral vaccine production and manufacture
EP4479025A1 (en) 2022-02-15 2024-12-25 Takeda Vaccines, Inc. Dengue vaccine batch mixing process
WO2023215383A1 (en) 2022-05-04 2023-11-09 Takeda Vaccines, Inc. Computer-based determination of flavivirus infectivity
WO2024108087A1 (en) 2022-11-18 2024-05-23 Takeda Vaccines, Inc. A method for determining the proportion of a live, attenuated flavivirus having a nucleotide sequence comprising at least one attenuation locus in a formulation
WO2024118740A1 (en) 2022-11-29 2024-06-06 Takeda Vaccines, Inc. Large-scale flaviviral vaccine production and manufacture
WO2025072259A1 (en) 2023-09-25 2025-04-03 Takeda Vaccines, Inc. Coadministration of tetravalent dengue vaccine with hpv vaccine
WO2025122855A1 (en) 2023-12-08 2025-06-12 Takeda Vaccines, Inc. A method for determining the concentration of residual vero cell genomic dna in a sample containing virus obtained from production in vero cells

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6184024B1 (en) * 1988-07-14 2001-02-06 The United States Of America As Represented By The Department Of Health And Human Services Chimeric and/or growth-restricted flaviviruses
US6676936B1 (en) * 1988-07-14 2004-01-13 The United States Of America As Represented By The Department Of Health And Human Services. Chimeric and/or growth-restricted flaviviruses
US5605793A (en) * 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US6962708B1 (en) * 1997-02-28 2005-11-08 Acambis, Inc. Chimeric flavivirus vaccines
US7192593B2 (en) * 1997-05-23 2007-03-20 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Use of recombinant parainfluenza viruses (PIVs) as vectors to protect against infection and disease caused by PIV and other human pathogens
US6541011B2 (en) * 1998-02-11 2003-04-01 Maxygen, Inc. Antigen library immunization
AU1813901A (en) * 1999-12-01 2001-06-12 Oravax, Inc Chimeric flavivirus vaccines
AU2003239932A1 (en) * 2002-05-31 2003-12-19 Acambis, Inc. Tetravalent dengue vaccines
US6966281B1 (en) * 2004-05-05 2005-11-22 Hale James R Internal combustion device and methods of use
FR2903605A1 (fr) * 2006-07-12 2008-01-18 Sanofi Pasteur Sa Methode d'immunisation contre les quatres serotypes de la dengue
FR2906724B1 (fr) * 2006-10-04 2009-03-20 Sanofi Pasteur Sa Methode d'immunisation contre les 4 serotypes de la dengue.
FR2909286B1 (fr) * 2006-12-01 2012-06-08 Sanofi Pasteur Methode d'immunisation contre les 4 serotypes de la dengue

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113637694A (zh) * 2013-03-15 2021-11-12 武田疫苗股份有限公司 用于疫苗中的登革热病毒嵌合式构建物的组合物及方法
US11931399B2 (en) 2013-03-15 2024-03-19 Takeda Vaccines, Inc. Compositions and methods for dengue virus chimeric constructions in vaccines
CN113637694B (zh) * 2013-03-15 2024-11-12 武田疫苗股份有限公司 用于疫苗中的登革热病毒嵌合式构建物的组合物及方法
US12186363B2 (en) 2013-03-15 2025-01-07 Takeda Vaccines, Inc. Compositions and methods for dengue virus chimeric constructions in vaccines

Also Published As

Publication number Publication date
IL189329A0 (en) 2008-06-05
US20080193477A1 (en) 2008-08-14
WO2007021672A3 (en) 2007-11-22
IL189329A (en) 2015-07-30
BRPI0614265A2 (pt) 2011-03-22
EP1924280A2 (en) 2008-05-28
JP2009504654A (ja) 2009-02-05
CA2618783A1 (en) 2007-02-22
AU2006280144B2 (en) 2012-06-14
AR055603A1 (es) 2007-08-29
AU2006280144A1 (en) 2007-02-22
MY151051A (en) 2014-03-31
EP1924280A4 (en) 2008-12-10
WO2007021672A2 (en) 2007-02-22
JP5227172B2 (ja) 2013-07-03
NO20081127L (no) 2008-05-07

Similar Documents

Publication Publication Date Title
TW200740458A (en) Vaccination against dengue virus infection
IL233634A0 (en) Methods, compositions and kits for treating medical conditions
MY160041A (en) Compositions and methods for treating parasitic infections
MY148635A (en) Anti-tat226 antibodies and immunoconjugates
TW200732349A (en) Anti-OX40L antibodies and methods using same
EA201070271A1 (ru) Пептиды для получения вакцины
UA94221C2 (en) Lipocalin protein
EA201101521A1 (ru) Способы лечения онкологических заболеваний, использующие эпиметаболические переключатели, многоаспектные внутриклеточные молекулы или факторы влияния
MX2009008430A (es) Anticuerpos anti-robo4 y sus usos.
GB0710529D0 (en) Vaccine
GB0515353D0 (en) Food
MY149705A (en) Pyridino-pyridinone derivatives, preparation therof, and therapeutic use thereof
EA201001322A1 (ru) Вакцины против хламидиоза
PH12013502194A1 (en) Antibodies to egfl7 and methods for their use
IL186325A0 (en) Tizanidine compositions and methods of treatment using the compositions
MX2009004866A (es) Vacuna para enfermedad de lyme canina.
TW200738751A (en) Anti-EphrinB2 antibodies and methods using same
WO2009009034A3 (en) Methods and compositions useful in the treatment of mucositis
SG136953A1 (en) Aqueous cleaning composition and method for using same
MX2009003022A (es) Composiciones y metodos para tratar picaduras de medusa.
EP1954296A4 (en) COMPOSITIONS FOR DETECTING INFLUENZA VIRUSES AND KITS AND METHODS BASED ON THE USE OF SAID COMPOSITIONS
MX2007005526A (es) Tratamiento de mastitis con enrofloxacino.
NO20091386L (no) Fenyloksyanilinderivater
ZA200802176B (en) Vaccination against dengue virus infection
IL186307A0 (en) Human glp-1 mimetibodies, compositions, methods and uses